Targeting ZNF410 for HbF reactivation
靶向 ZNF410 进行 HbF 重新激活
基本信息
- 批准号:10608727
- 负责人:
- 金额:$ 69.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAffectAllelesAnimal ModelAnimalsBindingBiologicalBiological AssayBiological ProcessBypassCHD4 geneCRISPR screenCell modelCellsChemicalsChromatinClinicalClinical TrialsDedicationsDefectDevelopmentDiseaseElementsErythrocytesErythroidErythropoiesisEvaluationEventExhibitsFetal HemoglobinFutureGene ExpressionGene Expression RegulationGene TargetingGenesGenomeGenomicsGoalsGrowthHematologyHematopoiesisHematopoieticHemoglobinHemoglobin concentration resultHemoglobinopathiesHomeostasisHumanIn VitroInvestigationKnock-outLeadLibrariesLogicMendelian disorderMolecularMolecular GeneticsMolecular TargetMusMutationNuRD complexNucleosomesOrthologous GenePharmaceutical ChemistryPharmacotherapyPhenotypePopulationProteinsRegulationRegulator GenesRegulatory ElementReporterRepressionRestRoleSafetySickle Cell AnemiaStructure-Activity RelationshipSystemTNFSF5 geneTherapeuticTherapeutic IndexToxic effectTranscription RepressorUpstream EnhancerXenograft procedurebeta Thalassemiaderepressiondrug developmentfunctional genomicsgamma Globingene repressiongene therapyhealth disparityhematopoietic engraftmentimmune modulating agentsimmunoregulationin vivoinhibitorlenalidomidemouse developmentnovelpomalidomidepromoterprotein complexprotein degradationscale upscreeningsmall moleculesuccesstargeted treatmenttherapeutic evaluationtherapeutic targettooltranscription factorubiquitin ligase
项目摘要
ABSTRACT
Hemoglobin disorders, such as sickle cell disease and β-thalassemia, comprise the most common monogenic
diseases of the world and yet, current treatments remain largely supportive and inadequate. Induction of fetal
hemoglobin (HbF) could bypass the fundamental genetic defects of adult hemoglobin that cause these
diseases. Recent gene therapy successes provide proof-of-concept that understanding the molecular control of
adult-stage HbF silencing can identify rational therapeutic targets. However, gene therapy cannot be scaled up
globally to match the scope of the clinical problem for the foreseeable future. Therefore, novel
pharmacotherapies are needed to induce HbF. The major HbF regulators BCL11A, ZBTB7A, and NuRD each
have on-target liabilities that could make therapeutic targeting challenging. Recently ZNF410 was discovered
to be a novel transcriptional repressor of HbF level during adult-stage erythropoiesis. ZNF410 has a narrow
biological action, which is to enhance the expression of CHD4. CHD4 possesses a unique array of 27
reiterated ZNF410 binding motifs at its promoter and upstream enhancer, an assemblage without comparison
in the rest of the genome. This study aims to investigate the: mechanisms whereby ZNF410 controls the
expression of CHD4 through homotypic motif clusters; requirements for ZNF410 and its orthologs throughout
development, homeostasis and hematopoiesis; and potential of targeted protein degradation of ZNF410 by
IMiD congeners as a therapeutic approach. Near-term goals are to define the role of protein-level cooperativity
and chromatin accessibility in binding to CHD4 by ZNF410 and the relationship between ZNF410 binding
events and CHD4 expression. These mechanistic studies will help identify vulnerabilities in this regulatory axis
that might be targeted therapeutically. Furthermore, the roles of ZNF410 throughout mouse development and
adulthood as well as in human hematopoiesis will be investigated. Constitutive and conditional alleles of
Zfp410 and its cognate regulatory elements at Chd4 in mice will be generated and characterized.
Requirements for ZNF410 throughout human erythropoiesis and hematopoiesis will be identified by bulk and
single cell gene expression and chromatin profiling in vitro and in vivo. Finally, tool compounds will be
generated to validate targeted protein degradation of ZNF410 by small molecules as a promising therapeutic
approach. Structural evaluation and systematic exploration of structure-activity relationships will be leveraged
to obtain instructive compounds to evaluate in ZNF410/Zfp410 sufficient and deficient cellular and animal
models the therapeutic premise that ZNF410 is a favorable therapeutic target for HbF induction in the β-
hemoglobinopathies. The long-term goal is to promote the development of drug-like small molecules that
ultimately could be used in clinical trials.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Evan Bauer其他文献
Daniel Evan Bauer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel Evan Bauer', 18)}}的其他基金
Chemotherapy-free cure of hemoglobin disorders through base editing
通过碱基编辑无需化疗即可治愈血红蛋白疾病
- 批准号:
10754114 - 财政年份:2023
- 资助金额:
$ 69.17万 - 项目类别:
Comprehensive characterization of variants underlying heart and blood diseases with CRISPR base editing
通过 CRISPR 碱基编辑全面表征心脏和血液疾病的变异
- 批准号:
10296877 - 财政年份:2021
- 资助金额:
$ 69.17万 - 项目类别:
Comprehensive characterization of variants underlying heart and blood diseases with CRISPR base editing
通过 CRISPR 碱基编辑全面表征心脏和血液疾病的变异
- 批准号:
10473734 - 财政年份:2021
- 资助金额:
$ 69.17万 - 项目类别:
Comprehensive characterization of variants underlying heart and blood diseases with CRISPR base editing
通过 CRISPR 碱基编辑全面表征心脏和血液疾病的变异
- 批准号:
10627940 - 财政年份:2021
- 资助金额:
$ 69.17万 - 项目类别:
Gene editing ELANE to understand and treat severe congenital neutropenia
基因编辑 ELANE 了解和治疗严重先天性中性粒细胞减少症
- 批准号:
10580862 - 财政年份:2020
- 资助金额:
$ 69.17万 - 项目类别:
Therapeutic BCL11A enhancer gene editing to induce fetal hemoglobin in β-hemoglobinopathy patients
治疗性 BCL11A 增强子基因编辑诱导 β 血红蛋白病患者胎儿血红蛋白
- 批准号:
10317505 - 财政年份:2020
- 资助金额:
$ 69.17万 - 项目类别:
Therapeutic BCL11A enhancer gene editing to induce fetal hemoglobin in β-hemoglobinopathy patients
治疗性 BCL11A 增强子基因编辑诱导 β 血红蛋白病患者胎儿血红蛋白
- 批准号:
10090251 - 财政年份:2020
- 资助金额:
$ 69.17万 - 项目类别:
Gene editing ELANE to understand and treat severe congenital neutropenia
基因编辑 ELANE 了解和治疗严重先天性中性粒细胞减少症
- 批准号:
10338097 - 财政年份:2020
- 资助金额:
$ 69.17万 - 项目类别:
Rectifying splicing mutations in blood disorders by gene editing
通过基因编辑纠正血液疾病中的剪接突变
- 批准号:
10531577 - 财政年份:2019
- 资助金额:
$ 69.17万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 69.17万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 69.17万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 69.17万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 69.17万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 69.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 69.17万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 69.17万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 69.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 69.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 69.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)